Currently, there are 114.19M common shares owned by the public and among those 93.24M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -18.66% and 11.22% over the past three months. ABSI shares are trading 24.81% year to date (YTD), with the 12-month market performance down to -36.63% lower. It has a 12-month low price of $2.45 and touched a high of $6.72 over the same period. ABSI has an average intraday trading volume of 5.41 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -29.15%, -13.43%, and -14.93% respectively.
Institutional ownership of Absci Corp (NASDAQ: ABSI) shares accounts for 63.12% of the company’s 114.19M shares outstanding.
It has a market capitalization of $375.58M and a beta (3y monthly) value of 2.12. The earnings-per-share (ttm) stands at -$0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.78% over the week and 11.97% over the month.
Earnings per share for the fiscal year are expected to increase by 28.03%, and 11.77% over the next financial year. EPS should grow at an annualized rate of 19.60% over the next five years, compared to -46.78% over the past 5-year period.
Looking at the support for the ABSI, a number of firms have released research notes about the stock. Needham stated their Buy rating for the stock in a research note on January 22, 2025, with the firm’s price target at $9. Guggenheim coverage for the Absci Corp (ABSI) stock in a research note released on October 02, 2024 offered a Buy rating with a price target of $10. Morgan Stanley was of a view on July 03, 2024 that the stock is Overweight, while Scotiabank gave the stock Sector Outperform rating on March 14, 2024, issuing a price target of $13. KeyBanc Capital Markets on their part issued Overweight rating on December 05, 2023.
